Figure 3.

TA1 increases left ventricular developed pressure (DevP) and rate-pressure product (RPP) without affecting heart rate (HR) or left ventricular end diastolic pressure (LVEDP), as opposed to dobutamine (Dob).

A, DevP increased progressively with increasing concentrations of both TA1 and Dob. B and C, HR (B) and LVEDP (C) underwent minor changes with TA1, yet both gradually increased with incremental concentrations of Dob. D, RPP increased progressively with increasing concentrations of both TA1 and Dob; 60 nmol/L TA1 increased RPP to the similar extent as 120 nmol/L Dob at lower HR (B). RPP was calculated as DevP×HR. As 60 nmol/L TA1 and 120 nmol/L Dob increased RPP to the similar extent, their effect is circled in D. n=15 (TA1) and 11 (Dob). Data shown are mean±SEM. Averages of the 2 time point measurements per substance concentration were compared. P values were obtained by paired t tests (baseline vs incremental concentrations of Dob or TA1) and unpaired t tests (60 nmol/L TA1 vs 120 nmol/L Dob). ****P<0.0001 vs TA1-zero baseline. †P<0.05, ††P<0.01, †††P<0.001, and ††††P=0.0001 vs Dob-zero baseline, respectively. ‡‡P<0.01 vs 120 nmol/L Dob. N for all time points is provided in Table S3.